# A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

Source: https://onco.cc/trials/nct06496971/  
OnCo record `nct06496971` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bevacizumab in glioma & glioblastoma and brain and spinal cord tumours, run by NaviFUS Corporation, now recruiting.

## Summary

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients is a phase 3 interventional study registered as NCT06496971 by NaviFUS Corporation, with 32 participants planned, started 2024-11-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: Bevacizumab, Microbubble and Low-Intensity Focused Ultrasound.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06496971
- Phase: 3
- Setting: A Prospective, Randomized, Standard of Care Controlled, Parallel, Open-Label, Multicenter Pivotal Study to Evaluate the Efficacy and Safety of Avastin® in Combination With NaviFUS System Compared With Avastin® Alone for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
- Sponsor: NaviFUS Corporation
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT06496971: https://clinicaltrials.gov/study/NCT06496971

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06496971.json